Maravai Life Sciences downgraded by UBS with a new price target
$MRVI
Biotechnology: Pharmaceutical Preparations
Health Care
UBS downgraded Maravai Life Sciences from Buy to Neutral and set a new price target of $16.00 from $20.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | Peer Perform | Wolfe Research | |
| 11/8/2024 | Outperform → Mkt Perform | William Blair | |
| 8/28/2024 | $10.00 | Overweight | Wells Fargo |
| 8/13/2024 | $11.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/10/2024 | $15.00 | Buy | Craig Hallum |
| 12/12/2023 | $10.00 → $8.00 | Neutral → Buy | BofA Securities |
| 8/8/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 5/23/2023 | $18.00 → $14.00 | Outperform → Neutral | Credit Suisse |
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November. On November 19, 2024, at 8:30 a.m. PST/ 11:30 a.m. EST, Kevin Herde, Chief Financial Officer, and Drew Burch, President, Nucleic Acid Production, will participate in a fireside chat at the Stifel Healthcare Conference in New York, NY. On November 21, 2024, at 2:00 a.m. PST/ 9:00 a.m. GMT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare C
Officinae Bio's breakthroughs in AI-enabled methodologies for nucleic manufacturing to enhance Maravai's mRNA manufacturing capabilities within the TriLink BioTechnologies business Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies. Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support t
Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $65.2 million, Net loss of $(176.0) million (including a goodwill impairment of $154.2 million), and Adjusted EBITDA of $12.7 million; andUpdated revenue guidance for the full year 2024 to be in the r
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that its CEO William "Trey" Martin, III has been appointed to the Company's Board of Directors, effective July 31, 2024. This strategic appointment underscores Martin's commitment to innovation, leadership capabilities, and deep industry knowledge. "We are thrilled to welcome Trey to our Board of Directors," said Carl Hull, Maravai's co-founder and Executive Chair of its Board of Directors. "Trey's extensive experience and depth of knowledge will bring valuable perspectives and enrich our collective
William "Trey" Martin, III assumes the role of Maravai's CEO Carl Hull to continue to serve as Executive Chairman SAN DIEGO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William "Trey" Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company's previously announced CEO succession plan. Carl Hull, Maravai's co-founder and prior interim CEO, will continue to serve as Maravai's Executive Chairman of the Board. "We are thri
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Robert ("Chip") Hance has stepped down from the Company's Board of Directors (the "Board") effective July 19, 2023, and that Dr. John DeFord has been appointed to the Board effective July 20, 2023. Mr. Hance, a 25-year veteran in the medical device industry, is set to become the Chairman of the Board of the Medical Device Innovation Consortium (MDIC) and stepped down from the Board in anticipation of the increased time commitment associated with that role. D
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $65.2 million, Net loss of $(176.0) million (including a goodwill impairment of $154.2 million), and Adjusted EBITDA of $12.7 million; andUpdated revenue guidance for the full year 2024 to be in the r
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 9502421. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.mara
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $73.4 million, Net loss of $(14.5) million, and Adjusted EBITDA of $16.9 million; andReaffirmed revenue guidance for the full year 2024 in the range of $265.0 million to $285.0 million. Partnerships and Innovation: TriLink BioTechnologies announced a collaboration with the John Hopkins University aimed at accelerating transformationa
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
Wolfe Research initiated coverage of Maravai Life Sciences with a rating of Peer Perform
William Blair downgraded Maravai Life Sciences from Outperform to Mkt Perform
Wells Fargo initiated coverage of Maravai Life Sciences with a rating of Overweight and set a new price target of $10.00
10-Q - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
Goldman Sachs analyst Matthew Sykes maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and lowers the price target from $8 to $7.
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter financial results. Bank of Montreal posted quarterly adjusted earnings of C$2.59 per share, missing market estimates of C$2.77 per share. The company's quarterly sales came in at C$7.988 billion missing expectations of C$8.046 billion, according to data from Benzinga Pro. Bank of Montreal shares declined 7.1% to $89.32 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers ReShape Lifesciences Inc. (NASDAQ:RSLS) shares jumped 82.8% to $0.3799 a day after it received the nod from the U.S. Patent And Trademark O
Gainers Innovative Eyewear (NASDAQ:LUCY) stock increased by 173.2% to $1.12 during Wednesday's regular session. The market value of their outstanding shares is at $19.6 million. Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 53.94% to $0.32. The company's market cap stands at $7.5 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 34.56% to $0.27. The company's market cap stands at $4.2 million. Apollomics (NASDAQ:APLM) shares increased by 28.89% to $0.34. The market value of their outstanding shares is at $36.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 25.07% to $0.2. The market value of their outstanding shares is at $4.5 million. Chromocell Therapeuti